United Therapeutics Corporation
United Therapeutics Corporation Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
From United Therapeutics Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
- Ralinepag and the IPF indication alone are expected to drive this growth.
- The launch of oral ralinepag is anticipated by mid-next year, assuming smooth FDA approval.
- Tyvaso DPI has shown 9% year-over-year growth, driven by increased patient demand.
- New formulations like Tyvaso DPI, Tyvaso SMI, and ralinepag DPI are expected to expand market reach in PH-ILD, PAH, IPF, and PPF.
- The company plans to invest in commercial sales force expansion mid-year to focus on capturing uncaptured markets.
2 more points from United Therapeutics Corporation's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what United Therapeutics Corporation said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- United Therapeutics is investing in expanding manufacturing capacity to support the growing demand for Tyvaso DPI and ralinepag.
- They will utilize the Danbury, Connecticut MannKind production plant and the new United Therapeutics North Carolina DPI facility.
- Sales force investments are planned to be deployed mid-2026 to expand reach and capture more of the addressable PH-ILD and PAH markets.
- Continued development and commercial scale-up of multiple product formulations (DPI, SMI, nebulized) for various indications including IPF and PAH.
2 more points from United Therapeutics Corporation's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what United Therapeutics Corporation said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company expects a strong demand trajectory, aiming for a $4 billion revenue run rate by the end of 2027, more than doubling current revenues driven by ralinepag and IPF indications.
- There is significant patient demand for Tyvaso DPI, with patient shipments growing for the last 5 months and increased patient graduation to higher doses.
- The launch of ralinepag oral formulation is expected mid-next year following anticipated FDA approval, targeting a multibillion-dollar market opportunity.
- Preparations for product launches, including IPF indications and ralinepag formulations, are underway with expanded sales force investments planned for mid-2026.
2 more points from United Therapeutics Corporation's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
United Therapeutics Corporation and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were United Therapeutics Corporation Q2 FY26 results?
- United Therapeutics projects a $4 billion revenue run rate by the end of 2027, more than doubling current revenues. - United Therapeutics aims to reach a $4 billion revenue run rate by the end of 2027, more than doubling current revenues.
What is United Therapeutics Corporation share price analysis?
United Therapeutics Corporation currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 21.4 with a market cap of $23,859. Investors should review the full earnings analysis for detailed insights.
Is United Therapeutics Corporation planning capital expenditure?
- United Therapeutics is investing in expanding manufacturing capacity to support the growing demand for Tyvaso DPI and ralinepag.
Keep United Therapeutics Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.